SCHEMBL3095902

SCHEMBL3095902

CS(=O)(=O)c1ccc(-c2ccc(=O)[nH]n2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.64
MEN1 O00255 1/20 0.64
KMT2A Q03164 1/20 0.64
CYP1A2 P05177 2/20 0.58
MAPT P10636 1/20 0.51
PDE3B Q13370 5/20 0.50
PDE3A Q14432 5/20 0.50
PDE4A P27815 3/20 0.50
PDE4B Q07343 3/20 0.50
PDE4C Q08493 3/20 0.50
PDE4D Q08499 3/20 0.50
AKR1B1 P15121 5/20 0.45
TP53 P04637 1/20 0.43
CYP2C9 P11712 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
CYP2C19 P33261 1/20 0.43
BLM P54132 1/20 0.43
PMP22 Q01453 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3452908 0.83 LMNA (0.80) LMNAMEN1KMT2ACYP1A2MAPT
SCHEMBL11035831 0.78 LMNA (1.00) LMNAMEN1KMT2ACYP1A2MAPT
SCHEMBL9687063 0.76 LMNA (0.69) LMNAMEN1KMT2ACYP1A2MAPT
SCHEMBL8758860 0.75 PTGS2 (0.43) PTGS2
SCHEMBL2152989 0.74 LMNA (0.67) LMNAMEN1KMT2ACYP1A2MAPT
SCHEMBL4122238 0.74 LMNA (0.67) LMNAMEN1KMT2ACYP1A2MAPT
SCHEMBL1392640 0.74 LMNA (0.67) LMNAMEN1KMT2ACYP1A2MAPT
SCHEMBL481916 0.74 LMNA (0.67) LMNAMEN1KMT2ACYP1A2MAPT
SCHEMBL928226 0.74 LMNA (0.67) LMNAMEN1KMT2ACYP1A2MAPT
SCHEMBL9687084 0.74 MAPT (0.50) LMNAMEN1KMT2ACYP1A2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2754660-B1 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2016-11-02 EP disclosed
US-9284300-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2016-03-15 US disclosed
US-9284300-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2016-03-15 US disclosed
US-20150011534-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2015-01-08 US disclosed
US-20150011534-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2015-01-08 US disclosed
US-20150011534-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2015-01-08 US disclosed
US-8927540-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2015-01-06 US disclosed
US-8927540-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2015-01-06 US disclosed
US-8927540-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2015-01-06 US disclosed
US-8921357-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2014-12-30 US disclosed
US-20130184260-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2013-07-18 US disclosed
US-20130184260-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2013-07-18 US disclosed
US-20130184261-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2013-07-18 US disclosed
US-20130184261-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2013-07-18 US disclosed
US-20100234354-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-16 US disclosed
US-20100234354-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-16 US disclosed
US-20100234354-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-16 US disclosed
CN-101743241-A pyridazinone derivates MERCK PATENT GMBH 2010-06-16 CN disclosed
EP-2164843-A1 PYRIDAZINONE DERIVATES Merck Patent GmbH (DE) 2010-03-24 EP disclosed
WO-2009006959-A1 PYRIDAZINONE DERIVATES MERCK PATENT GMBH (DE) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184261-A1 PYRIDAZINONE DERIVATIVES MET, RET, ERBB2 LMNA 2672/4885MEN1 164/4885KMT2A 904/4885
US-20130184260-A1 PYRIDAZINONE DERIVATIVES MET, RET, ERBB2 LMNA 2906/4885MEN1 173/4885KMT2A 1033/4885
US-20150011534-A1 PYRIDAZINONE DERIVATIVES MET, RET, ERBB2 LMNA 2906/4885MEN1 173/4885KMT2A 1033/4885
US-20100234354-A1 PYRIDAZINONE DERIVATIVES MET, RET, ERBB2 LMNA 3076/4885MEN1 221/4885KMT2A 1065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.